• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Revvity Announces Financial Results for the Third Quarter of 2023

    10/30/23 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $RVTY alert in real time by email
    • Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth
    • GAAP EPS of $0.08; Adjusted EPS from continuing operations of $1.18
    • Updates full year 2023 guidance

    Revvity, Inc. (NYSE:RVTY), today reported financial results for the third quarter ended October 1, 2023.

    The Company reported GAAP earnings per share of $0.08, as compared to $0.67 in the same period a year ago. GAAP revenue for the quarter was $671 million, as compared to $712 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $69 million, as compared to $111 million for the same period a year ago. GAAP operating profit margin from continuing operations was 10.3% as a percentage of revenue, as compared to 15.6% in the same period a year ago.

    Adjusted earnings per share from continuing operations for the quarter was $1.18, as compared to $1.21 in the same period a year ago. Adjusted revenue for the quarter was $671 million, as compared to $712 million in the same period a year ago. Adjusted operating income was $185 million, as compared to $224 million for the same period a year ago. Adjusted operating profit margin was 27.5% as a percentage of adjusted revenue, as compared to 31.4% in the same period a year ago.

    Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.

    "We executed well during the third quarter in an increasingly challenging end market environment," said Prahlad Singh, president and chief executive officer of Revvity. "During this period of increased market uncertainty, we will focus our efforts on those factors we can control to ensure the Company emerges from this period in an even stronger and more agile position."

    Financial Overview by Reporting Segment for the Third Quarter

    Life Sciences

    • Third quarter 2023 revenue was $308 million, as compared to $313 million in the same period a year ago. Reported revenue decreased 2% and organic revenue decreased 3% as compared to the same period a year ago.
    • Third quarter 2023 adjusted operating income was $114 million, as compared to $117 million in the same period a year ago.
    • Third quarter 2023 adjusted operating profit margin was 37.1% as a percentage of adjusted revenue, as compared to 37.4% in the same period a year ago.

    Diagnostics

    • Third quarter 2023 revenue was $363 million, as compared to $399 million in the same period a year ago. Reported revenue decreased 9% and organic revenue decreased 10% as compared to the same period a year ago.
    • Third quarter 2023 adjusted operating income was $82 million, as compared to $123 million in the same period a year ago.
    • Third quarter 2023 adjusted operating profit margin was 22.5% as a percentage of adjusted revenue, as compared to 30.9% in the same period a year ago.

    Updates Full Year 2023 Guidance

    For the full year 2023, the Company now forecasts total revenue of $2.72-$2.74 billion and adjusted earnings per share of $4.53-$4.57. This guidance assumes no additional contribution from COVID related revenues.

    Guidance for the full year 2023 is provided on a non-GAAP basis and cannot be reconciled to the closest GAAP measures without unreasonable effort due to the unpredictability of the amounts and timing of events affecting the items the Company excludes from these non-GAAP measures. The timing and amounts of such events and items could be material to the Company's results prepared in accordance with GAAP.

    Webcast Information

    The Company will discuss its third quarter 2023 results and its outlook for business trends during a webcast on October 30, 2023, at 8:00 a.m. Eastern Time. A live audio webcast and presentation will be available on the Investors section of the Company's website, ir.revvity.com.

    Use of Non-GAAP Financial Measures

    In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.

    Factors Affecting Future Performance

    This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "estimates", "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and divestitures, license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant disruption in our information technology systems, or cybercrime; (12) our ability to realize the full value of our intangible assets; (13) our failure to adequately protect our intellectual property; (14) the loss of any of our licenses or licensed rights; (15) the manufacture and sale of products exposing us to product liability claims; (16) our failure to maintain compliance with applicable government regulations; (17) regulatory changes; (18) our failure to comply with healthcare industry regulations; (19) economic, political and other risks associated with foreign operations; (20) our ability to obtain future financing; (21) restrictions in our credit agreements; (22) significant fluctuations in our stock price; (23) reduction or elimination of dividends on our common stock; and (24) other factors which we describe under the caption "Risk Factors" in our most recent quarterly report on Form 10-Q and in our other filings with the Securities and Exchange Commission. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

    About Revvity

    At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

    With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

    Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

    Revvity, Inc. and Subsidiaries
    CONDENSED CONSOLIDATED INCOME STATEMENTS
     
     

    Three Months Ended

    Nine Months Ended

    (In thousands, except per share data) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022
     
     
    Revenue

    $

    670,739

     

    $

    711,803

     

    $

    2,054,670

     

    $

    2,570,608

     

     
    Cost of revenue

     

    298,223

     

     

    304,759

     

     

    898,457

     

     

    1,017,108

     

    Selling, general and administrative expenses

     

    250,249

     

     

    242,743

     

     

    765,828

     

     

    781,189

     

    Research and development expenses

     

    53,039

     

     

    53,521

     

     

    166,982

     

     

    167,081

     

     
    Operating income from continuing operations

     

    69,228

     

     

    110,780

     

     

    223,403

     

     

    605,230

     

     
    Interest income

     

    (23,450

    )

     

    (667

    )

     

    (53,768

    )

     

    (2,024

    )

    Interest expense

     

    25,486

     

     

    25,931

     

     

    74,231

     

     

    81,447

     

    Change in fair value of financial securities

     

    13,587

     

     

    5,106

     

     

    12,842

     

     

    14,321

     

    Other expense (income), net

     

    3,002

     

     

    (1,732

    )

     

    38,501

     

     

    (1,904

    )

     
    Income from continuing operations, before income taxes

     

    50,603

     

     

    82,142

     

     

    151,597

     

     

    513,390

     

     
    Provision for income taxes

     

    18,134

     

     

    12,634

     

     

    35,661

     

     

    98,211

     

     
    Income from continuing operations

     

    32,469

     

     

    69,508

     

     

    115,936

     

     

    415,179

     

     
    (Loss) income from discontinued operations

     

    (22,972

    )

     

    15,839

     

     

    498,595

     

     

    26,342

     

     
    Net income

    $

    9,497

     

    $

    85,347

     

    $

    614,531

     

    $

    441,521

     

     
     
    Diluted earnings per share:
    Income from continuing operations

    $

    0.26

     

    $

    0.55

     

    $

    0.93

     

    $

    3.28

     

     
    (Loss) income from discontinued operations

     

    (0.18

    )

     

    0.13

     

     

    3.98

     

     

    0.21

     

     
    Net income

    $

    0.08

     

    $

    0.67

     

    $

    4.90

     

    $

    3.49

     

     
     
    Weighted average diluted shares of common stock outstanding

     

    124,203

     

     

    126,540

     

     

    125,335

     

     

    126,544

     

     
     
    ABOVE PREPARED IN ACCORDANCE WITH GAAP
     
     
    Additional supplemental information (1):
    (per share, continuing operations)
     
    GAAP EPS from continuing operations

    $

    0.26

     

    $

    0.55

     

    $

    0.93

     

    $

    3.28

     

    Amortization of intangible assets

     

    0.73

     

     

    0.72

     

     

    2.20

     

     

    2.22

     

    Debt extinguishment costs

     

    (0.00

    )

     

    (0.00

    )

     

    (0.03

    )

     

    (0.00

    )

    Purchase accounting adjustments

     

    0.01

     

     

    0.08

     

     

    0.02

     

     

    0.36

     

    Acquisition and divestiture-related costs

     

    0.09

     

     

    0.07

     

     

    0.63

     

     

    0.20

     

    Change in fair value of financial securities

     

    0.11

     

     

    0.04

     

     

    0.10

     

     

    0.11

     

    Significant litigation matters and settlements

     

    -

     

     

    0.00

     

     

    -

     

     

    (0.00

    )

    Significant environmental matters

     

    -

     

     

    -

     

     

    0.01

     

     

    -

     

    Restructuring and other, net

     

    0.09

     

     

    0.02

     

     

    0.13

     

     

    0.12

     

    Tax on above items

     

    (0.25

    )

     

    (0.24

    )

     

    (0.73

    )

     

    (0.77

    )

    Significant tax items

     

    0.14

     

     

    (0.03

    )

     

    0.13

     

     

    (0.03

    )

    Adjusted EPS from continuing operations

    $

    1.18

     

    $

    1.21

     

    $

    3.39

     

    $

    5.50

     

     
    (1) amounts may not sum due to rounding
     
     
    Revvity, Inc. and Subsidiaries
    REVENUE AND OPERATING INCOME (LOSS)
     
     
     
    Three Months Ended Nine Months Ended
    (In thousands, except percentages) October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022
     
    Adjusted revenue and operating income
     
    Reported revenue

    $

    670,739

     

    $

    711,803

     

    $

    2,054,670

     

    $

    2,570,608

     

    Revenue purchase accounting adjustments

     

    206

     

     

    203

     

     

    618

     

     

    609

     

    Adjusted revenue

     

    670,945

     

     

    712,006

     

     

    2,055,288

     

     

    2,571,217

     

     
    Reported operating income from continued operations

     

    69,228

     

     

    110,780

     

     

    223,403

     

     

    605,230

     

    OP%

     

    10.3

    %

     

    15.6

    %

     

    10.9

    %

     

    23.5

    %

    Amortization of intangible assets

     

    90,920

     

     

    91,525

     

     

    275,489

     

     

    280,469

     

    Purchase accounting adjustments

     

    1,080

     

     

    9,621

     

     

    3,057

     

     

    45,594

     

    Acquisition and divestiture-related costs

     

    12,550

     

     

    8,475

     

     

    59,080

     

     

    25,865

     

    Significant litigation matters and settlements

     

    -

     

     

    629

     

     

    -

     

     

    (632

    )

    Significant environmental matters

     

    -

     

     

    -

     

     

    1,132

     

     

    -

     

    Restructuring and other, net

     

    10,832

     

     

    2,774

     

     

    15,936

     

     

    15,443

     

    Adjusted operating income

    $

    184,610

     

    $

    223,804

     

    $

    578,097

     

    $

    971,969

     

    OP%

     

    27.5

    %

     

    31.4

    %

     

    28.1

    %

     

    37.8

    %

     
    Segment revenue and segment operating income
     
    Life Sciences

    $

    307,855

     

    $

    312,783

     

    $

    972,649

     

    $

    945,484

     

    Diagnostics

     

    363,090

     

     

    399,223

     

     

    1,082,639

     

     

    1,625,733

     

    Revenue purchase accounting adjustments

     

    (206

    )

     

    (203

    )

     

    (618

    )

     

    (609

    )

    Reported revenue

     

    670,739

     

     

    711,803

     

     

    2,054,670

     

     

    2,570,608

     

     
     
    Life Sciences

     

    114,192

     

     

    116,881

     

     

    371,410

     

     

    357,661

     

     

    37.1

    %

     

    37.4

    %

     

    38.2

    %

     

    37.8

    %

    Diagnostics

     

    81,741

     

     

    123,428

     

     

    241,414

     

     

    668,981

     

     

    22.5

    %

     

    30.9

    %

     

    22.3

    %

     

    41.1

    %

    Corporate

     

    (11,323

    )

     

    (16,505

    )

     

    (34,727

    )

     

    (54,673

    )

    Subtotal reportable segments operating income

     

    184,610

     

     

    223,804

     

     

    578,097

     

     

    971,969

     

     
    Amortization of intangible assets

     

    (90,920

    )

     

    (91,525

    )

     

    (275,489

    )

     

    (280,469

    )

    Purchase accounting adjustments

     

    (1,080

    )

     

    (9,621

    )

     

    (3,057

    )

     

    (45,594

    )

    Acquisition and divestiture-related costs

     

    (12,550

    )

     

    (8,475

    )

     

    (59,080

    )

     

    (25,865

    )

    Significant litigation matters and settlements

     

    -

     

     

    (629

    )

     

    -

     

     

    632

     

    Significant environmental matters

     

    -

     

     

    -

     

     

    (1,132

    )

     

    -

     

    Restructuring and other, net

     

    (10,832

    )

     

    (2,774

    )

     

    (15,936

    )

     

    (15,443

    )

    Reported operating income from continued operations

    $

    69,228

     

    $

    110,780

     

    $

    223,403

     

    $

    605,230

     

     
     
    REPORTED REVENUE AND REPORTED OPERATING INCOME (LOSS) PREPARED IN ACCORDANCE WITH GAAP
     
    Revvity, Inc. and Subsidiaries
    CONDENSED CONSOLIDATED BALANCE SHEETS
     
     
     
    (In thousands) October 1, 2023 January 1, 2023
     
    Current assets:
    Cash and cash equivalents

    $

    1,136,721

    $

    454,358

    Marketable securities

     

    292,971

     

    -

    Accounts receivable, net

     

    644,574

     

    612,780

    Inventories, net

     

    435,696

     

    405,462

    Other current assets

     

    403,275

     

    122,254

    Current assets of discontinued operations

     

    -

     

    1,693,704

    Total current assets

     

    2,913,237

     

    3,288,558

     
    Property, plant and equipment, net

     

    489,747

     

    482,950

    Operating lease right-of-use assets

     

    156,143

     

    188,351

    Intangible assets, net

     

    3,085,253

     

    3,377,174

    Goodwill

     

    6,470,139

     

    6,481,768

    Other assets, net

     

    307,029

     

    311,054

    Total assets

    $

    13,421,548

    $

    14,129,855

     
    Current liabilities:
    Current portion of long-term debt

    $

    727,539

    $

    470,929

    Accounts payable

     

    188,302

     

    272,826

    Accrued expenses and other current liabilities

     

    532,004

     

    527,863

    Current liabilities of discontinued operations

     

    -

     

    272,865

    Total current liabilities

     

    1,447,845

     

    1,544,483

     
    Long-term debt

     

    3,152,454

     

    3,923,347

    Long-term liabilities

     

    993,046

     

    1,109,181

    Operating lease liabilities

     

    133,922

     

    169,968

    Total liabilities

     

    5,727,267

     

    6,746,979

     
    Total stockholders' equity

     

    7,694,281

     

    7,382,876

    Total liabilities and stockholders' equity

    $

    13,421,548

    $

    14,129,855

     
     
    PREPARED IN ACCORDANCE WITH GAAP
     
    Revvity, Inc. and Subsidiaries
    CONSOLIDATED STATEMENTS OF CASH FLOWS
     
     
    Three Months Ended Nine Months Ended
    October 1, 2023 October 2, 2022 October 1, 2023 October 2, 2022
    (In thousands) (In thousands)
     
     
    Operating activities:
    Net income

    $

    9,497

     

    $

    85,347

     

    $

    614,531

     

    $

    441,521

     

    Loss (income) from discontinued operations, net of income taxes

     

    22,972

     

     

    (15,839

    )

     

    (498,595

    )

     

    (26,342

    )

    Income from continuing operations

     

    32,469

     

     

    69,508

     

     

    115,936

     

     

    415,179

     

    Adjustments to reconcile income from continuing operations
    to net cash provided by (used in) continuing operations:
    Stock-based compensation

     

    10,703

     

     

    10,112

     

     

    34,229

     

     

    39,776

     

    Restructuring and other, net

     

    10,832

     

     

    2,774

     

     

    15,936

     

     

    15,443

     

    Depreciation and amortization

     

    108,263

     

     

    104,735

     

     

    326,201

     

     

    322,766

     

    Change in fair value of contingent consideration

     

    633

     

     

    (2,132

    )

     

    1,718

     

     

    (769

    )

    Amortization of deferred debt financing costs and accretion of discounts

     

    1,982

     

     

    2,194

     

     

    5,800

     

     

    6,046

     

    Change in fair value of financial securities

     

    13,587

     

     

    5,106

     

     

    12,842

     

     

    14,321

     

    Debt extinguishment income

     

    (77

    )

     

    (580

    )

     

    (3,422

    )

     

    (92

    )

    Unrealized foreign exchange loss

     

    -

     

     

    -

     

     

    23,679

     

     

    -

     

    Amortization of acquired inventory revaluation

     

    -

     

     

    11,315

     

     

    -

     

     

    45,039

     

    Changes in assets and liabilities which provided (used) cash, excluding
    effects from companies acquired:
    Accounts receivable, net

     

    (20,697

    )

     

    39,803

     

     

    (30,913

    )

     

    120,138

     

    Inventories

     

    (8,059

    )

     

    (12,681

    )

     

    (34,834

    )

     

    (44,475

    )

    Accounts payable

     

    (36,169

    )

     

    (18,308

    )

     

    (85,394

    )

     

    (27,968

    )

    Accrued expenses and other

     

    (82,710

    )

     

    (89,881

    )

     

    (322,995

    )

     

    (360,089

    )

    Net cash provided by (used in) operating activities of continuing operations

     

    30,757

     

     

    121,965

     

     

    58,783

     

     

    545,315

     

    Net cash (used in) provided by operating activities of discontinued operations

     

    (64,242

    )

     

    37,987

     

     

    (164,124

    )

     

    (4,663

    )

    Net cash (used in) provided by operating activities

     

    (33,485

    )

     

    159,952

     

     

    (105,341

    )

     

    540,652

     

     
    Investing activities:
    Capital expenditures

     

    (22,357

    )

     

    (13,030

    )

     

    (57,252

    )

     

    (59,502

    )

    Purchases of investments

     

    (1,000

    )

     

    (22,760

    )

     

    (6,000

    )

     

    (45,010

    )

    Purchases of US Treasury Securities

     

    -

     

     

    -

     

     

    (831,219

    )

     

    -

     

    Proceeds from US Treasury Securities

     

    450,000

     

     

    550,000

     

    Proceeds from notes receivables

     

    -

     

     

    8,890

     

     

    -

     

     

    8,890

     

    Proceeds from disposition of businesses and assets

     

    153

     

     

    4,610

     

     

    153

     

     

    5,664

     

    Cash paid for acquisitions, net of cash, cash equivalents and restricted cash acquired

     

    (1,400

    )

     

    (2,133

    )

     

    (2,086

    )

     

    (7,768

    )

    Net cash provided by (used in) investing activities of continuing operations

     

    425,396

     

     

    (24,423

    )

     

    (346,404

    )

     

    (97,726

    )

    Net cash provided by (used in) investing activities of discontinued operations

     

    9,473

     

     

    1,917

     

     

    2,074,734

     

     

    (9,441

    )

    Net cash provided by (used in) investing activities

     

    434,869

     

     

    (22,506

    )

     

    1,728,330

     

     

    (107,167

    )

     
    Financing Activities:
    Payments on borrowings

     

    -

     

     

    -

     

     

    -

     

     

    (220,000

    )

    Proceeds from borrowings

     

    -

     

     

    -

     

     

    -

     

     

    220,000

     

    Payments of term loan

     

    -

     

     

    (50,000

    )

     

    -

     

     

    (500,000

    )

    Payments of senior debt

     

    (467,138

    )

     

    (7,472

    )

     

    (517,973

    )

     

    (7,472

    )

    Payment of debt issuance costs

     

    -

     

     

    (15

    )

    Settlement of cash flow hedges

     

    -

     

     

    -

     

     

    -

     

     

    (762

    )

    Net (payments) proceeds on other credit facilities

     

    (13

    )

     

    343

     

     

    7,218

     

     

    (482

    )

    Payments for acquisition-related contingent consideration

     

    -

     

     

    -

     

     

    (10,117

    )

     

    (5

    )

    Proceeds from issuance of common stock under stock plans

     

    506

     

     

    413

     

     

    3,721

     

     

    6,254

     

    Purchases of common stock

     

    (110,715

    )

     

    (89

    )

     

    (384,014

    )

     

    (56,137

    )

    Dividends paid

     

    (8,689

    )

     

    (8,835

    )

     

    (26,327

    )

     

    (26,502

    )

    Net cash used in financing activities of continuing operations

     

    (586,049

    )

     

    (65,640

    )

     

    (927,507

    )

     

    (585,106

    )

     
    Effect of exchange rate changes on cash, cash equivalents, and restricted cash

     

    (10,699

    )

     

    (17,427

    )

     

    (28,270

    )

     

    (51,404

    )

     
    Net (decrease) increase in cash, cash equivalents, and restricted cash

     

    (195,364

    )

     

    54,379

     

     

    667,212

     

     

    (203,025

    )

    Cash, cash equivalents, and restricted cash at beginning of period

     

    1,333,322

     

     

    361,933

     

     

    470,746

     

     

    619,337

     

    Cash, cash equivalents, and restricted cash at end of period

    $

    1,137,958

     

    $

    416,312

     

    $

    1,137,958

     

    $

    416,312

     

     
     
    Supplemental disclosure of cash flow information:
    Reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total shown in the consolidated statements of cash flows:
    Cash and cash equivalents

    $

    1,136,721

     

    $

    400,741

     

    $

    1,136,721

     

    $

    400,741

     

    Restricted cash included in other current assets

     

    1,237

     

     

    284

     

     

    1,237

     

     

    284

     

    Restricted cash included in other assets

     

    -

     

     

    288

     

     

    -

     

     

    288

     

    Cash and cash equivalents included in current assets of discontinued operations

     

    -

     

     

    14,999

     

     

    -

     

     

    14,999

     

    Total cash, cash equivalents and restricted cash

    $

    1,137,958

     

    $

    416,312

     

    $

    1,137,958

     

    $

    416,312

     

     
    PREPARED IN ACCORDANCE WITH GAAP
     
    Revvity, Inc. and Subsidiaries
    RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (1)
     
     
    Revvity
    Three Months Ended
    October 1, 2023
    Organic revenue growth:
    Reported revenue growth from continuing operations

    -6%

    Less: effect of foreign exchange rates

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Organic revenue growth from continuing operations

    -7%

    Less: effect of COVID products

    -8%

    Non-COVID organic revenue growth from continuing operations

    1%

     
     
    Life Sciences
    Three Months Ended
    October 1, 2023
    Organic revenue growth:
    Reported revenue growth from continuing operations

    -2%

    Less: effect of foreign exchange rates

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Organic revenue growth from continuing operations

    -3%

     
     
    Diagnostics
    Three Months Ended
    October 1, 2023
    Organic revenue growth:
    Reported revenue growth from continuing operations

    -9%

    Less: effect of foreign exchange rates

    1%

    Less: effect of acquisitions including purchase accounting adjustments and impact of divested businesses

    0%

    Organic revenue growth from continuing operations

    -10%

     
     
    (1) amounts may not sum due to rounding
     
     

    Explanation of Non-GAAP Financial Measures

    We report our financial results in accordance with GAAP. However, management believes that, in order to more fully understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash, non-recurring or other items, which result from facts and circumstances that vary in frequency and impact on continuing operations. Accordingly, we present non-GAAP financial measures as a supplement to the financial measures we present in accordance with GAAP. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by adjusting for certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management's ability to make useful forecasts. Management believes these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

    We use the term "adjusted revenue" to refer to GAAP revenue, including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "adjusted revenue growth" to refer to the measure of comparing current period adjusted revenue with the corresponding period of the prior year.

    We use the term "organic revenue" to refer to GAAP revenue, excluding the effect of foreign currency changes and revenue from recent acquisitions and divestitures and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules. We use the related term "organic revenue growth" to refer to the measure of comparing current period organic revenue with the corresponding period of the prior year. We use the related term "non-COVID organic revenue growth" to refer to the measure of comparing current period organic revenue excluding revenue from COVID related products and services with the corresponding period of the prior year excluding revenue from COVID related products and services.

    We use the term "adjusted gross margin" to refer to GAAP gross margin, excluding amortization of intangible assets and inventory fair value adjustments related to business acquisitions, asset impairments, and including purchase accounting adjustments for revenue from contracts acquired in acquisitions that will not be fully recognized due to business combination accounting rules. We use the related term "adjusted gross margin percentage" to refer to adjusted gross margin as a percentage of adjusted revenue.

    We use the term "adjusted SG&A expense" to refer to GAAP SG&A expense, excluding amortization of intangible assets, purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, asset impairments, and significant environmental charges. We use the related term "adjusted SG&A percentage" to refer to adjusted SG&A expense as a percentage of adjusted revenue.

    We use the term "adjusted R&D expense" to refer to GAAP R&D expense, excluding amortization of intangible assets and purchase accounting adjustments. We use the related term "adjusted R&D percentage" to refer to adjusted R&D expense as a percentage of adjusted revenue.

    We use the term "adjusted net interest and other expense" to refer to GAAP net interest and other expense, excluding adjustments for mark-to-market accounting on post-retirement benefits, changes in foreign exchange and interest associated with acquisitions and divestitures, changes in the value of financial securities and debt extinguishment costs.

    We use the term "adjusted operating income," to refer to GAAP operating income, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding amortization of intangible assets, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, asset impairments, and restructuring and other charges. We use the related terms "adjusted operating profit percentage," "adjusted operating profit margin," or "adjusted operating margin" to refer to adjusted operating income as a percentage of adjusted revenue.

    We use the term "adjusted earnings per share," or "adjusted EPS," to refer to GAAP earnings per share, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, and excluding discontinued operations, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    We use the term "adjusted earnings per share from continuing operations," to refer to GAAP earnings per share from continuing operations, including revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules, amortization of intangible assets, debt extinguishment costs, other purchase accounting adjustments, acquisition and divestiture-related expenses, significant litigation matters and settlements, significant environmental charges, changes in the value of financial securities, disposition of businesses and assets, net, changes in foreign exchange and interest associated with acquisitions and divestitures, asset impairments and restructuring and other charges. We also exclude adjustments for mark-to-market accounting on post-retirement benefits, therefore only our projected costs have been used to calculate this non-GAAP measure. We also adjust for any tax impact related to the above items and exclude the impact of significant tax events.

    Management includes or excludes the effect of each of the items identified below in the applicable non-GAAP financial measure referenced above for the reasons set forth below with respect to that item:

    • Amortization of intangible assets—purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.
    • Debt extinguishment costs—we incur costs and income related to the extinguishment of debt; including make-whole payments to debt holders, accelerated amortization of debt fees and discounts, and expense or income from hedges to lock in make-whole payments. We exclude the impact of these items from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Revenue from contracts acquired in acquisitions that will not be fully recognized due to accounting rules—accounting rules require us to account for the fair value of revenue from contracts assumed in connection with our acquisitions. As a result, our GAAP results reflect the fair value of those revenues, which is not the same as the revenue that otherwise would have been recorded by the acquired entity. We include such revenue in our non-GAAP measures because we believe the fair value of such revenue does not accurately reflect the performance of our ongoing operations for the period in which such revenue is recorded.
    • Other purchase accounting adjustments—accounting rules require us to adjust various balance sheet accounts, including inventory, fixed assets and deferred rent balances to fair value at the time of the acquisition. As a result, the expenses for these items in our GAAP results are not the same as what would have been recorded by the acquired entity. Accounting rules also require us to estimate the fair value of contingent consideration at the time of the acquisition, and any subsequent changes to the estimate or payment of the contingent consideration and purchase accounting adjustments are charged to expense or income. We exclude the impact of any changes to contingent consideration from our non-GAAP measures because we believe these expenses or benefits do not accurately reflect the performance of our ongoing operations for the period in which such expenses or benefits are recorded.
    • Acquisition and divestiture-related expenses—we incur legal, due diligence, stay bonuses, incentive awards, stock-based compensation, interest, foreign exchange gains and losses, integration expenses, rebranding expenses, and other costs related to acquisitions and divestitures. We exclude these expenses from our non-GAAP measures because we believe they do not reflect the performance of our ongoing operations.
    • Asset impairments—we incur expense related to asset impairments. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Restructuring and other charges—restructuring and other charges consist of employee severance, other exit costs as well as the cost of terminating certain lease agreements or contracts as well as costs associated with relocating facilities. Management does not believe such costs accurately reflect the performance of our ongoing operations for the period in which such costs are reported.
    • Adjustments for mark-to-market accounting on post-retirement benefits—we exclude adjustments for mark-to-market accounting on post-retirement benefits, and therefore only our projected costs are used to calculate our non-GAAP measures. We exclude these adjustments because they do not represent what we believe our investors consider to be costs of producing our products, investments in technology and production, and costs to support our internal operating structure.
    • Significant litigation matters and settlements—we incur expenses related to significant litigation matters, including the costs to settle or resolve various claims and legal proceedings. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Significant environmental charges—we incur expenses related to significant environmental charges. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such charges were incurred.
    • Disposition of businesses and assets, net—we exclude the impact of gains or losses from the disposition of businesses and assets from our adjusted earnings per share. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Impact of foreign currency changes on the current period—we exclude the impact of foreign currency associated with acquisitions and divestitures from these measures by using the prior period's foreign currency exchange rates for the current period because foreign currency exchange rates are subject to volatility and can obscure underlying trends.
    • Impact of significant tax events—we exclude the impact of significant tax events, such as the Tax Cuts and Jobs Act of 2017. Management does not believe the impact of significant tax events accurately reflects the performance of our ongoing operations for the periods in which the impact of such events was recorded.
    • Changes in value of financial securities—we exclude the impact of changes in the value of financial securities. Management does not believe such gains or losses accurately reflect the performance of our ongoing operations for the period in which such gains or losses are reported.
    • Depreciation of fixed assets ceased upon reporting the business as held for sale—we exclude the impact of ceasing depreciation of fixed assets that are held for sale. Management does not believe such charges accurately reflect the performance of our ongoing operations for the periods in which such expenses were ceased.

    # # #

    The tax effect for discontinued operations is calculated based on the authoritative guidance in the Financial Accounting Standards Board's Accounting Standards Codification 740, Income Taxes. The tax effect for amortization of intangible assets, inventory fair value adjustments related to business acquisitions, changes to the fair values assigned to contingent consideration, debt extinguishment costs, other costs related to business acquisitions and divestitures, significant litigation matters and settlements, significant environmental charges, changes in the fair value of financial securities, adjustments for mark-to-market accounting on post-retirement benefits, disposition of businesses and assets, net, restructuring and other charges, and the revenue from contracts acquired with various acquisitions is calculated based on operational results and applicable jurisdictional law, which contemplates tax rates currently in effect to determine our tax provision. The tax effect for the impact from foreign currency exchange rates on the current period is calculated based on the average rate currently in effect to determine our tax provision.

    The non-GAAP financial measures described above are not meant to be considered superior to, or a substitute for, our financial statements prepared in accordance with GAAP. There are material limitations associated with non-GAAP financial measures because they exclude charges that have an effect on our reported results and, therefore, should not be relied upon as the sole financial measures by which to evaluate our financial results. Management compensates and believes that investors should compensate for these limitations by viewing the non-GAAP financial measures in conjunction with the GAAP financial measures. In addition, the non-GAAP financial measures included in this earnings announcement may be different from, and therefore may not be comparable to, similar measures used by other companies.

    Each of the non-GAAP financial measures listed above is also used by our management to evaluate our operating performance, communicate our financial results to our Board of Directors, benchmark our results against our historical performance and the performance of our peers, evaluate investment opportunities including acquisitions and discontinued operations, and determine the bonus payments for senior management and employees.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231030443131/en/

    Get the next $RVTY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RVTY

    DatePrice TargetRatingAnalyst
    12/15/2025$110.00Buy → Neutral
    BofA Securities
    12/9/2025$105.00Neutral
    Goldman
    10/16/2025Neutral
    Guggenheim
    5/1/2025$115.00Neutral → Buy
    UBS
    1/10/2025$130.00Outperform → Mkt Perform
    Bernstein
    12/13/2024$138.00Neutral → Buy
    BofA Securities
    10/15/2024$125.00 → $140.00Equal Weight → Overweight
    Barclays
    8/28/2024$130.00Equal Weight
    Wells Fargo
    More analyst ratings

    $RVTY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Revvity to Present at Upcoming Investor Conferences

    Revvity, Inc. (NYSE:RVTY), today announced it will present at the following investor conferences: Raymond James 47th Annual Institutional Investors Conference Monday, March 2, 2026 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 46th Annual Health Care Conference Tuesday, March 3, 2026 2:30 p.m. ET - Prahlad Singh, president and chief executive officer Barclays 28th Annual Global Healthcare Conference Tuesday, March 10, 2026 10:30 a.m. ET - Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be available on the Events section of the Company's website. Rep

    2/17/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026

    New launches in high-content imaging, detection, and automation help labs accelerate drug discovery workflows from sample to insight Revvity, Inc. (NYSE:RVTY) announced the launch of multiple new discovery platforms and technologies at SLAS2026, which are designed to accelerate high-throughput drug discovery workflows. Making their debut at the conference in Boston, February 7-11, are the Opera Phenix OptIQ™ high-content screening system, the EnVision Nexus™ One multimode plate reader, and the AssayMate™ workstation, alongside other recently introduced solutions spanning sample preparation, screening, advanced imaging, and lab automation. At booth #612, Revvity will showcase an expanded

    2/5/26 8:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Revvity downgraded by BofA Securities with a new price target

    BofA Securities downgraded Revvity from Buy to Neutral and set a new price target of $110.00

    12/15/25 9:57:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Revvity with a new price target

    Goldman initiated coverage of Revvity with a rating of Neutral and set a new price target of $105.00

    12/9/25 8:53:25 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Revvity

    Guggenheim initiated coverage of Revvity with a rating of Neutral

    10/16/25 8:27:52 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    SEC Filings

    View All

    SEC Form DEFA14A filed by Revvity Inc.

    DEFA14A - REVVITY, INC. (0000031791) (Filer)

    3/16/26 8:06:48 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form DEF 14A filed by Revvity Inc.

    DEF 14A - REVVITY, INC. (0000031791) (Filer)

    3/16/26 8:01:24 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form PRE 14A filed by Revvity Inc.

    PRE 14A - REVVITY, INC. (0000031791) (Filer)

    3/6/26 4:06:15 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Gonzales Anita

    4 - REVVITY, INC. (0000031791) (Issuer)

    3/18/26 4:05:13 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Gonzales Anita was granted 1,721 shares, increasing direct ownership by 42% to 5,799 units (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    3/10/26 4:05:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Officer Victor Miriame exercised 1,862 shares at a strike of $95.74 and sold $180,856 worth of shares (1,862 units at $97.13) (SEC Form 4)

    4 - REVVITY, INC. (0000031791) (Issuer)

    2/26/26 4:05:03 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Financials

    Live finance-specific insights

    View All

    Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025

    Fourth quarter revenue of $772 million; 6% revenue growth; 4% organic growth Fourth quarter GAAP EPS of $0.87; Adjusted EPS from continuing operations of $1.70 Initiates full year 2026 guidance Revvity, Inc. (NYSE:RVTY) today reported financial results for the fourth quarter and full year ended December 28, 2025. Fourth Quarter 2025 The Company reported GAAP earnings per share of $0.87, as compared to $0.78 in the same period a year ago. Revenue for the quarter was $772 million, as compared to $729 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $112 million, as compared to $119 million for the same period a year ago.

    2/2/26 6:00:00 AM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity Board Declares Quarterly Dividend

    The Board of Directors of Revvity, Inc. (NYSE:RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 8, 2026 to all shareholders of record at the close of business on April 17, 2026. About Revvity At Revvity, "impossible" is inspiration, and "can't be done" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what's possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening,

    1/26/26 4:05:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance

    Revvity, Inc. (NYSE:RVTY), today announced that it will release its fourth quarter and full year 2025 financial results prior to market open on Monday, February 2, 2026. The Company will host a conference call the same day at 8:00 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section of the Company's website. Update on Financial Performance The Company is also providing the following preliminary financial results for the fourth quarter 2025: Reported and organic revenue growth for the fourth

    1/12/26 4:15:00 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $RVTY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 4:30:07 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Revvity Inc.

    SC 13G/A - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:28:28 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SC 13G filed by Revvity Inc.

    SC 13G - REVVITY, INC. (0000031791) (Subject)

    11/14/24 1:22:34 PM ET
    $RVTY
    Biotechnology: Laboratory Analytical Instruments
    Industrials